Proteus Digital Health’s Ingestible Sensor Reports When Granny Takes Her Meds
Executive Summary
A signal transmitted by the embedded sensor when a pill dissolves is picked up by a Bluetooth-enabled skin patch and sent to a remote phone app, notifying a designated caregiver that dosing is on track – or not. Both Novartis and Otsuka are trying the technology, and Proteus is developing its own line of digitized generics.
You may also be interested in...
FDA Approves First Digital Pill: Otsuka/Proteus' Abilify MyCite
Otsuka plans a slow, measured launch of Abilify MyCite, developed with Proteus Health. The product includes an ingested sensor that sends a signal to a wearable patch and an app that tracks ingestion, activity and mood to potentially improve management of psychiatric care.
FDA Approves First Digital Pill: Otsuka/Proteus' Abilify MyCite
Otsuka plans a slow, measured launch of Abilify MyCite, developed with Proteus Health. The product includes an ingested sensor that sends a signal to a wearable patch and an app that tracks ingestion, activity and mood to potentially improve management of psychiatric care.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.